Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease: HELP
Articles by Jingjing Chen
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Jingjing Chen wrote the following 2 articles about Crohn Disease.
 
+ Citations + Abstracts
1 Clinical Trial Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. 2017

Sands, Bruce E / Chen, Jingjing / Feagan, Brian G / Penney, Mark / Rees, William A / Danese, Silvio / Higgins, Peter D R / Newbold, Paul / Faggioni, Raffaella / Patra, Kaushik / Li, Jing / Klekotka, Paul / Morehouse, Chris / Pulkstenis, Erik / Drappa, Jörn / van der Merwe, René / Gasser, Robert A. ·Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: bruce.sands@mssm.edu. · MedImmune, Gaithersburg, Maryland. · Robarts Clinical Trials, University of Western Ontario, London, Ontario. · MedImmune, Cambridge, United Kingdom. · Humanitas Clinical and Research Center, Milan, Italy. · University of Michigan, Ann Arbor, Michigan. · MedImmune, Mountain View, California. · Amgen, Thousand Oaks, California. ·Gastroenterology · Pubmed #28390867.

ABSTRACT: BACKGROUND & AIMS: MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). We analyzed its safety and efficacy in treatment of CD in a phase 2a study. METHODS: We conducted a double-blind, placebo-controlled study of 119 adults with moderate to severe CD failed by treatment with tumor necrosis factor antagonists. Patients were randomly assigned (1:1) to groups given MEDI2070 (700 mg) or placebo intravenously at weeks 0 and 4. Patients received open-label MEDI2070 (210 mg) subcutaneously every 4 weeks from weeks 12 to 112. The CD Activity Index was used to measure disease activity. RESULTS: The primary outcome, clinical response (either a 100-point decrease in CD Activity Index score from baseline or clinical remission, defined as CD Activity Index score <150) at week 8 occurred in 49.2% of patients receiving MEDI2070 (n = 59) compared with 26.7% receiving placebo (n = 60; absolute difference, 22.5%; 95% confidence interval, 5.6%-39.5%; P = .010). Clinical response at week 24 occurred in 53.8% of patients who continued to receive open-label MEDI2070 and in 57.7% of patients who had received placebo during the double-blind period and open-label MEDI2070 thereafter. The most common adverse events were headache and nasopharyngitis. Higher baseline serum concentrations of IL22, a cytokine whose expression is induced by IL23, were associated with greater likelihood of response to MEDI2070 compared with placebo. CONCLUSIONS: In a phase 2a trial of patients with moderate to severe Crohn's disease who had failed treatment with tumor necrosis factor antagonists, 8 and 24 weeks of treatment with MEDI2070 were associated with clinical improvement. ClinicalTrials.gov ID: NCT01714726.

2 Article Alvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients. 2019

Jang, Janice / Kwok, Benjamin / Zhong, Hua / Xia, Yuhe / Grucela, Alexis / Bernstein, Mitchell / Remzi, Feza / Hudesman, David / Chen, Jingjing / Axelrad, Jordan / Chang, Shannon. ·Division of Gastroenterology and Hepatology, New York University Langone Health, 240 East 38th Street, 23rd Floor, New York, NY, 10016, USA. · Department of Internal Medicine, New York University Langone Health, New York, NY, USA. · Department of Population Health, New York University Langone Health, New York, NY, USA. · Department of Surgery, New York University Langone Health, New York, NY, USA. · Department of Internal Medicine, Stanford University Medical Center, Stanford, CA, USA. · Division of Gastroenterology and Hepatology, New York University Langone Health, 240 East 38th Street, 23rd Floor, New York, NY, 10016, USA. Shannon.Chang@nyulangone.org. ·Dig Dis Sci · Pubmed #31522323.

ABSTRACT: BACKGROUND: Postoperative ileus (POI) is a temporary delay of coordinated intestinal peristalsis. Alvimopan, an oral peripherally acting mu-opioid receptor antagonist approved for accelerating gastrointestinal recovery, has never been studied specifically in patients with inflammatory bowel disease (IBD). AIM: To investigate the efficacy of alvimopan in preventing POI among IBD patients. METHODS: A retrospective chart review was conducted on 246 IBD patients undergoing bowel surgery between 2012 and 2017. Data collected included demographics, IBD subtype, length of stay (LOS), postoperative gastrointestinal symptoms, and administration of alvimopan. The primary outcome was POI; secondary gastrointestinal recovery outcomes were: time to first flatus, time to first bowel movement, time to tolerating a liquid diet, time to tolerating solid food, and LOS. RESULTS: When compared with the control group, patients in the alvimopan group had shorter times to tolerating liquids and solids, first flatus, and first bowel movements (p < 0.01). LOS was shorter in the alvimopan group when compared with controls (p < 0.01). The overall incidence of POI was higher in controls than in the alvimopan group (p = 0.07). For laparoscopic surgeries, the incidence of POI was also higher in controls than in the alvimopan group (p < 0.01). On multivariable analysis, alvimopan significantly decreased time to all gastrointestinal recovery endpoints when compared to controls (p < 0.01). CONCLUSIONS: Alvimopan is effective in accelerating time to gastrointestinal recovery and reducing POI in IBD patients. While the benefits of alvimopan have been demonstrated previously, this is the first study of the efficacy of alvimopan in IBD patients.